AstraZeneca under which AstraZeneca received a license to three of our MEK inhibitors for
cancer, including selumetinib, which is currently in multiple Phase 2 clinical trials.
September 2007 focused on the discovery, development and commercialization of novel
therapeutics in cancer and inflammation. The most advanced drug is ARRY-382, a cFMS inhibitor
for cancer, which is currently in a Phase 1 clinical trial.
January 2003, which was expanded in 2005, 2008, and 2009, and is focused on the discovery,
development and commercialization of novel therapeutics. The most advanced drug is GDC-0068,
an AKT inhibitor for cancer, which is currently in a Phase 2 trial.
each company's small-molecule Checkpoint kinase 1 (Chk-1) program. The programs include
Genentech's compound GDC-0425 (RG7602) and Array's compound, GDC-0575, both of which
are in Phase 1 clinical trials in patients with cancer.
develop and commercialize our MEK inhibitor, MEK162, and other MEK inhibitors identified in the
agreement. MEK162 is currently in numerous Phase 1b and Phase 2 clinical trials in patients with
which resulted in the joint discovery of danoprevir, a novel small molecule inhibitor of the Hepatitis
C Virus NS3/4A protease. Roche Holding AG acquired danoprevir from InterMune in 2010.
Danoprevir is currently in Phase 2b clinical trials.
from our inception in 1998 through June 30, 2012. In fiscal 2012, we spent $56.7 million in research and
development expenses for proprietary drug discovery, compared to $63.5 million and $72.5 million for
fiscal years 2011 and 2010, respectively.
from our collaboration partners from inception through June 30, 2012, including $174 million in initial
payments from our strategic collaborations with Amgen, Genentech and Novartis we entered into over the
past 32 months. These three collaborations entitle Array to receive up to over $2.2 billion in additional
potential milestone payments if all clinical and commercialization milestones under the agreements are
achieved, double digit royalties and/or commercial co-detailing rights. With our other existing partnered
programs, Array is entitled to receive a total of over $3.6 billion in additional potential milestone payments
if we or our collaborators achieve the drug discovery, development and commercialization objectives
detailed in those agreements. We also have the potential to earn royalties on any resulting product sales
or share in the proceeds from development or commercialization arrangements resulting from 11 drug
research and development programs.
develops and markets safe and effective small molecule drugs to treat patients afflicted with cancer and
inflammatory diseases. We intend to accomplish this through the following strategies:
commercialize or co-promote drugs we wholly own or for which we retain development rights in
certain geographic areas.
early-stage programs for continued research and development to receive research funding plus
significant milestone payments and royalties.
research funding, success-based milestone payments, co-detailing rights and/or royalties on product
sales. These agreements may also be structured to share in the proceeds received from a collaborator
resulting from the further development or commercialization of resulting drugs.
provide funding, development, manufacturing and commercial resources and may seek co-development
or co-commercialization rights worldwide or limited to certain geographic areas. We plan to advance and
commercialize our most promising development assets internally, which we believe will maximize their
value. We are also identifying certain programs to partner earlier during discovery or preclinical
development with the goal of optimizing the potential return for Array on these programs.
out-licensed certain proprietary drug programs for further research, development and commercialization.
Our largest or most advanced collaborations include our agreements with Amgen, ASLAN
Pharmaceuticals, AstraZeneca, Genentech, InterMune/ Roche and Novartis. Under some of these
collaborations, such as with Novartis for MEK162, we continue development work that is funded all or in
part by our partners. Under some of our other partnered programs, our involvement in the development or
research phase has ended but we retain the right to receive clinical and commercialization milestones
and/or royalties on sales of any products covered by the collaboration. We also have research
partnerships with leading pharmaceutical and biotechnology companies for which we design, create and
optimize drug candidates and conduct preclinical testing across a broad range of therapeutic areas on
targets selected by our partners. In certain of these partnerships, we also perform process research and
development, perform clinical development and manufacture clinical supplies.
revenue we receive within and outside the U.S. can be found in
elsewhere in this Annual Report.